US OptionsDetailed Quotes
XBI250516C92000
- 0.03
- +0.02+200.00%
15min DelayClose May 12 16:00 ET
0.03High0.03Low
0.03Open0.01Pre Close1 Volume271 Open Interest92.00Strike Price3.00Turnover64.44%IV15.83%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0161Delta0.0075Gamma2648.33Leverage Ratio-0.0206Theta0.0001Rho42.55Eff Leverage0.0033Vega
SPDR S&P Biotech ETF Stock Discussion
Sign in to post a comment
On May 11, 2025, President Trump announced plans to sign an executive order aimed at dramatically reducing prescription drug prices by 30-80% through a "most favored nation" policy. He later tweeted that prices would drop by 59%.
Trump stated, "America will no longer be taken advantage of. We'll pay the same as the lowest-price countries globally, saving trillions and significantly reducing healthcare costs for our people."
Following the announcement, majo...
Trump stated, "America will no longer be taken advantage of. We'll pay the same as the lowest-price countries globally, saving trillions and significantly reducing healthcare costs for our people."
Following the announcement, majo...
+1
28
3
39
A big day today, J Powow speaks, and the dots get plotted 😆
I will start with QQQ/ND and VIX, and then I will move to individual stocks. I don't own these and don't necessarily recommend buying them. I use them as sentiment and market bias/direction indicators.
I will be upfront and say my bias is up. How high doesn't really matter to me. I don't own the MAG 7. I just want to see willing buyers. I'm not nieve and am hedged for downside. but I have been buying a lot of individual ...
I will start with QQQ/ND and VIX, and then I will move to individual stocks. I don't own these and don't necessarily recommend buying them. I use them as sentiment and market bias/direction indicators.
I will be upfront and say my bias is up. How high doesn't really matter to me. I don't own the MAG 7. I just want to see willing buyers. I'm not nieve and am hedged for downside. but I have been buying a lot of individual ...
+33
48
3
5
Options Trading Newsletter Issue #203 from Substack.
SYNTHETIC Stock ON XBI
The SPDR S&P Biotech ETF (XBI) is an equal-weighted ETF that tracks the S&P Biotechnology Select Industry Index. Unlike market-cap-weighted ETFs, XBI gives equal exposure to small, mid, and large biotech stocks. This makes it more volatile compared to other biotech ETFs like IBB, which is more weighted toward large-cap biotech firms.
XBI Price Action Analysis
– XBI has been on...
SYNTHETIC Stock ON XBI
The SPDR S&P Biotech ETF (XBI) is an equal-weighted ETF that tracks the S&P Biotechnology Select Industry Index. Unlike market-cap-weighted ETFs, XBI gives equal exposure to small, mid, and large biotech stocks. This makes it more volatile compared to other biotech ETFs like IBB, which is more weighted toward large-cap biotech firms.
XBI Price Action Analysis
– XBI has been on...
12
1
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
bullish engulfing candle on daily, lets see if it hits our target $90 
What happened: In recent weeks, $Janux Therapeutics (JANX.US)$ has seen significant insider buying, notably from RA Capital Management, which acquired shares worth approximately $25.3M.
Big picture: Janux's stock has been volatile, trading near its 52-week low. Investor sentiment remains cautious amidst broader biotech sector challenges.
Key Developments:
📊 Positive Clinical Data: JANX007 showed impressive results in Phase 1 trials for metastatic castration-resistant prost...
Big picture: Janux's stock has been volatile, trading near its 52-week low. Investor sentiment remains cautious amidst broader biotech sector challenges.
Key Developments:
📊 Positive Clinical Data: JANX007 showed impressive results in Phase 1 trials for metastatic castration-resistant prost...
1
from Substack MyTradeHunter Newsletter
Market Scorecard
Market is weak with NQ dropping more than 7% and ES more by 5%. On contrast HSI has remained strong in anticipation of positive news flows coming out from the CCP Meetings in China, ongoing.
Trade Scorecard
IBIT Call Ratio (Update)
IBIT has hit roller coaster with selloff to a low of $46.07. Price has since recovered to $51.44.
We closed the short call 57C on 27 February when IBIT hit lows of $46.90 for $0...
Market Scorecard
Market is weak with NQ dropping more than 7% and ES more by 5%. On contrast HSI has remained strong in anticipation of positive news flows coming out from the CCP Meetings in China, ongoing.
Trade Scorecard
IBIT Call Ratio (Update)
IBIT has hit roller coaster with selloff to a low of $46.07. Price has since recovered to $51.44.
We closed the short call 57C on 27 February when IBIT hit lows of $46.90 for $0...
+3
4
1
$SPDR S&P Biotech ETF (XBI.US)$ big bearish flow coming in looking like a hedge. Potential put play, small size.
$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?
1
1
No comment yet
105386937 : MAGA
小AJ : Trump's nb has a sense of being at Tokyo University.
砸锅卖铁变韭菜 : Here we go again, it's been raised, and then lowered again.